Key result
Incretin-based therapies lower systolic blood pressure up to ~11 mmHg in obesity and reduce medication burden.
Why the study?
Incretin-based therapies produce significant weight loss and lower blood pressure in people with obesity, creating a new clinical situation where patients may require less antihypertensive therapy and prompting a potential transition toward management that addresses adiposity alongside blood pressure.
Do incretin-based therapies reduce blood pressure and the need for antihypertensive medications in patients with obesity and arterial hypertension?
Do incretin-based therapies reduce blood pressure and the need for antihypertensive medications in patients with obesity and arterial hypertension?
Answers are grounded in this paper and cite their sources.
Incretin-based therapies such as semaglutide, tirzepatide, and CagriSema achieve substantial weight loss and clinically meaningful blood pressure reductions in patients with obesity-related hypertension, frequently necessitating careful reassessment and potential de-escalation of background antihypertensive medications.
Obesity and hypertension often coexist in the same person and reinforce each other. Treatment of hypertension in people with obesity has been based mainly on lifestyle changes and the gradual addition of antihypertensive drugs. The development of GLP-1 receptor agonists and combined GIP/GLP-1 agonists has transformed the treatment of obesity, with implications beyond weight loss. These therapies can produce significant weight loss, but they also lower blood pressure and improve several other cardiometabolic risk factors. Recent data suggest that the reduction in blood pressure is largely related to weight loss, but is not necessarily fully explained by it. Effects on natriuresis, endothelial function, inflammation, neurohormonal activity, and circulating volume may represent additional mechanisms. In practice, this creates a new situation: a patient who loses significant weight may need less antihypertensive therapy. Our aim is to examine the relationship between obesity and hypertension, the clinical evidence on semaglutide, tirzepatide, and newer incretin-based therapies, as well as the possible transition from an approach focused solely on blood pressure toward management that also addresses adiposity as part of the disease mechanism.
No takes yet. Share an insight, caveat, or question.
Nelaj et al. (2026) conducted a review in Obesity and arterial hypertension. Incretin-based therapies (GLP-1 receptor agonists, semaglutide, tirzepatide, CagriSema) vs. Placebo was evaluated on Blood pressure reduction and antihypertensive medication burden. Incretin-based therapies lower systolic blood pressure by 3.4 to 10.9 mmHg in patients with obesity and reduce the need for antihypertensive medications.
Synapse has enriched 10 related papers. Consider them for comparative context: